Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 7/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 7/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18159819 | 0.89 | CYP11B1 (0.43) | CYP11B1CYP11B2CHRNB2CHRNB1CHRNB4 | |
| SCHEMBL18151541 | 0.84 | PIK3CB (0.40) | CYP11B1CYP11B2TNFPRMT5WDR77 | |
| SCHEMBL18150993 | 0.81 | CYP11B1 (0.41) | CYP11B1CYP11B2TNFRIPK1 | |
| SCHEMBL18151397 | 0.80 | PIK3CB (0.44) | CYP11B1CYP11B2PIK3CGRIPK1 | |
| SCHEMBL18150724 | 0.79 | CYP11B2 (0.47) | CYP11B1CYP11B2CYP19A1TNF | |
| SCHEMBL29794973 | 0.79 | PRMT5 (0.36) | TNFPRMT5WDR77 | |
| SCHEMBL18151377 | 0.79 | PRMT5 (0.36) | TNFPRMT5WDR77 | |
| SCHEMBL18151456 | 0.79 | TNF (0.41) | CYP11B1CYP11B2PIK3CGTNFRIPK1 | |
| SCHEMBL29987453 | 0.79 | TNF (0.41) | CYP11B1CYP11B2PIK3CGTNFRIPK1 | |
| SCHEMBL16814799 | 0.78 | P2RX7 (0.44) | PIK3CGTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| EP-4493221-A2 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212727-A | Targeted bifunctional degradants | 耶鲁大学 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024182772-A2 | MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | CYP11B1 4776/4885CYP11B2 4699/4885CHRNB2 3331/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | CYP11B1 3816/4885CYP11B2 3800/4885CHRNB2 2099/4885 |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, SSB | CYP11B1 4806/4885CYP11B2 4729/4885CHRNB2 3288/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | CYP11B1 415/4885CYP11B2 430/4885CHRNB2 3366/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | CYP11B1 4473/4885CYP11B2 4352/4885CHRNB2 1276/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | CYP11B1 415/4885CYP11B2 430/4885CHRNB2 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.